联合检测HE4和CA125在女性盆腔恶性肿瘤诊断中的价值  

Diagnostic performances of HE4 and CA125 for the detection of malignant pelvic tumors in patients with various gynecologic diseases

作　　者：葛多英[1] 孙伟莉[1] 袁媛[1] 陶健[1] 何娟娟[1] 殷文文[1] 

机构地区：[1]安徽省蚌埠医学院第一附属医院,安徽蚌埠233004

出　　处：《中国卫生检验杂志》2013年第3期717-719,共3页Chinese Journal of Health Laboratory Technology

摘　　要：目的:探讨联合检测血清人附睾上皮分泌蛋白4(HE4)和糖类抗原125(CA125)在盆腔恶性肿瘤诊断中的价值。方法:对66例健康体检者、59例盆腔良性肿瘤患者以及50例盆腔恶性肿瘤患者分别采用酶联免疫吸附法和微粒子酶免疫分析技术检测血清HE4和CA125含量并做统计学分析。结果:盆腔恶性肿瘤患者HE4和CA125水平均高于正常对照组和良性病变组。HE4和CA125的联合检测显著提高了盆腔恶性肿瘤诊断效能。结论:HE4的诊断价值与CA125相当,尽管每个标志物各有优缺点,在盆腔恶性肿瘤诊断中联合检测HE4和CA125,优于单个指标检测。Objective： To evaluate the clinical value in diagnosis of malignant pelvic tumors by combined determination of human epididymis gene product 4（HE4） and CA125. Methods： The serum HE4 and CA125 were detected by enzyme - linked immuno sorbent assay and microparticle chemiluminescent immunoassay in 66 healthy adults, 59 patients with benign pelvic tumors and 50 patients with malignant pelvic tumors. Then a statistical analysis was performed on these results. Results： In the patients with malignant pelvic tumors, the serum levels of HE4 and CA125 were higher than those in normal control group and the benign pelvic tumors group. Combining predictors can significantly improve the diagnosis efficiency of malignant pelvic tumors. Conclusion： HE4 demonstrated comparable diagnostic performances to CA125, though each marker had its own strengths and weaknesses. Combining CA125 and HE4 might be more advantageous than either one alone.

关 键 词：人附睾上皮分泌蛋白4 糖类抗原125 盆腔恶性肿瘤 

分 类 号：R737.3[医药卫生—肿瘤]